US2019192637A1PendingUtilityA1

Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

58
Assignee: REMEDOR BIOMED LTDPriority: Aug 16, 2007Filed: Mar 5, 2019Published: Jun 27, 2019
Est. expiryAug 16, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Saher Hamed
A61P 39/04A61P 43/00A61P 9/10A61P 7/04A61P 3/02A61P 31/00A61K 38/22A61K 38/19A61K 38/39A61K 9/0014A61K 38/43A61P 17/02A61K 38/36A61K 31/198A61K 47/32A61K 9/06A61K 31/70A61K 31/21A61K 38/1816
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

Claims

exact text as granted — not AI-modified
1 - 18 . (canceled) 
     
     
         19 . A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby treating ischemia in the subject. 
     
     
         20 . The method of  claim 19 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         21 . The method of  claim 19 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         22 . The method of  claim 19 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         23 . The method of  claim 19 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         24 . The method of  claim 19 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         25 . The method of  claim 20 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         26 . The method of  claim 19 , wherein wound healing is promoted in the subject. 
     
     
         27 . The method of  claim 19 , wherein connective tissue reconstruction is promoted in the subject. 
     
     
         28 . A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject.

Join the waitlist — get patent alerts

Track US2019192637A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.